Expert Interview
A second look: Discussing with a provider the commercial outlook for Abeona Therapeutics' Zevaskyn and projections for treatment for RDEB
Ticker(s): ABEO, KRYSInstitution: University of Colorado
- Professor of Pediatrics at University of Colorado, Pediatric Director of the Epidermolysis Bullosa Multidisciplinary Program
- Manages 75+ EB patients
- Research interests in pediatric polypharmacy and clinical care of EB patients
How many Recessive Dystrophic Epidermolysis Bullosa patients do you manage?
Added By: wilson_adminWhat has been your overall experience with Zevaskyn?
Added By: wilson_adminWhat is the outlook for Zevaskyn in your QTC over the next few quarters?
Added By: wilson_adminOutcome and outlook for first patient
Added By: sf fund mgrNumber of patients you treat whom you will recommend Zevaskyn to and number currently in queue
Added By: sf fund mgrAre You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
